Tag Archives: Pharma

Trump pressures 17 pharma CEOs to cut US drug prices – Reuters

Trump pressures 17 pharma CEOs to cut US drug prices  Reuters Trump Demands That Drugmakers Lower Some of Their U.S. Prices by September  The New York Times Trump’s drug price ultimatum sets pharma firms scrambling  CNBC Trump calls for price cuts on prescription drugs within 60 days in letters to Eli Lilly, Pfizer, other drugmakers  NBC News Trump threatens drug giants with crackdown over …

Read More »

Moderna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end – Fierce Pharma

Moderna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end  Fierce Pharma Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow  CNBC Moderna will lay off 10% of employees, Massachusetts-based company announces  CBS News Vaccine maker Moderna cuts hundreds of jobs; CEO says ‘every effort’ made to avoid layoffs  The Business Journals Moderna …

Read More »

Trump is demanding drugmakers lower prices within 60 days. Pharma experts say it’s unlikely to happen.

Trump is demanding drugmakers lower prices within 60 days. Pharma experts say it’s unlikely to happen.

Prescription drugs Donald Trump Health care policy Tariffs See all topics Facebook Tweet Email Link President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ones available to patients in other countries — though industry experts don’t expect the pharmaceutical companies to acquiesce. Trump sent letters to 17 …

Read More »

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy – Fierce Pharma

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy  Fierce Pharma Trump drove firing of FDA official  Politico Are we sure Vinay Prasad’s ouster is positive for biotech?  statnews.com FDA’s Prasad Exits Following Political Backlash Over Sarepta  Bloomberg.com FDA’s top vaccine official leaves post after less than four months  The Guardian Source link

Read More »

Exclusive | KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business – The Wall Street Journal

Exclusive | KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business  The Wall Street Journal KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business  Yahoo Finance KKR & Co. Acquires Majority Ownership Stake In HCRx  Nasdaq KKR buys HealthCare Royalty Partners as firm deepens bet on life sciences  Endpoints News KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the …

Read More »

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027 – Fierce Pharma

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027  Fierce Pharma Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook  CNBC Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop  Investor’s Business Daily Merck to Lay Off Workers and Narrows Guidance as Earnings Fall – WSJ  The Wall Street Journal Our Q2 2025 financial results  Merck.com …

Read More »

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca to invest  billion in the U.S. as pharma tariffs weigh

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered …

Read More »

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion – Fierce Pharma

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion  Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial  BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes  Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking  Stocktwits Luspatercept Plus …

Read More »